PRECLINICAL EVALUATION OF THERAPIES FOR MICROSPORIDIAL INFECTION 

NIH GUIDE, Volume 25, Number 10, March 29, 1996

 

RFP AVAILABLE:  NIH-NIAID-DAIDS-97-02

 

P.T. 34



Keywords:

  Chemotherapy 

  Infectious Diseases/Agents 

 

National Institute of Allergy and Infectious Diseases

 

The Opportunistic Infections Research Branch, Therapeutics Research

Program, Division of AIDS, National Institute of Allergy and

Infectious Diseases (NIAID), NIH, has a requirement to develop

therapies for the treatment of AIDS and associated opportunistic

infections.  The purpose of this RFP is: 1) to develop, standardize,

and validate a murine model of microsporidiosis that is appropriate

to testing new therapies, and 2) to develop, standardize, and

validate an in vitro system to screen potential new drugs against

microsporidial infection.  The emphasis of the resulting contract

will be to fill the gaps in knowledge and methodologies regarding

research on Enterocytozoon bieneusi.  Therefore, the primary in vivo

and in vitro models should utilize E. bieneusi as the infectious

agent.  The Government anticipates that the first year will focus on

development and validation of models.  Evaluation of therapies will

commence after the initial development period upon approval of the E.

bieneusi models, and efforts to improve the models may continue in

subsequent contract years.  Additional, alternative, validated in

vivo and in vitro models using other species of parasites in the

phylum Microspora will also be conducted under certain conditions.

Offerors must provide scientific justification for their selection of

alternative series of Microspora for these studies.  At the time of

proposal, Offerors should propose a murine model and an in vitro

model for standardization and validation under the contract using E.

bieneusi; alternative models using other species of microsporidia

should be justified in their selection, validated, and readily

available at the time of proposal.

 

It is anticipated that one cost reimbursement, level-of-effort type

contract will be awarded for a period of five years beginning on or

about July 15, 1997.  It is estimated that 1,750% total effort will

be needed for this acquisition during the five-year period.

 

RFP NIH-NIAID-DAIDS-97-02 will be available electronically on or

about April 15, 1996, and may be accessed through either the NIH

Gopher or the NIH Home Page by using the following electronic mail

addresses and instructions:

 

1) To access the NIH Gopher: Point your gopher client to

GOPHER.NIH.GOV PORT 70.  (You should now be in the NIH Gopher.)

Select "Grant and Research Information," then select "R&D Request for

Proposals" (RFP).

 

2) NIH Home Page (via the World Wide Web):  Access the NIH Home Page

by using http://www.nih.gov.  Once you are at the NIH Home Page,

select "Grants and Contracts," then select "R&D Requests for

Proposals (RFP)."

 

Responses to this RFP will be due on August 15, 1996.  Any

responsible offeror may submit a proposal which will be considered by

the Government.  This advertisement does not commit the Government to

award a contract.

 

INQUIRIES

 

Inquiries regarding this RFP may be directed to:

 

Phil Hastings

Contract Management Branch

National Institute of Allergy and Infectious Diseases

6003 Executive Boulevard, Room 3C07 - MSC 7610

Bethesda, MD  20892-7610

Telephone:  (301) 496-0194

FAX:  (301) 402-0972

Email:  ph23k@nih.gov

 

No collect calls will be accepted.

 

.

Return to 1996 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.